MIAMI--(BUSINESS WIRE)--Nov. 17, 2005--DOR BioPharma, Inc. (AMEX:DOR) (“DOR”, or the “Company”) today announced it has completed a feasibility study with Dowpharma(SM) contract manufacturing services, a business unit of The Dow Chemical Company (NYSE:DOW), focused on the expression of three recombinant heavy chain botulinum fragments used in the development of BT-VACC(TM), DOR’s proprietary mucosal botulinum vaccine. BT-VACC(TM) is designed to protect against botulinum toxin poisoning, one of the top three bioterrorism threats identified by the U.S. government and the most poisonous natural substance known to man. Using its Pfenex Expression Technology(TM), Dowpharma achieved a ten-fold increase in expression levels over the E. coli method previously used by DOR.
